{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:48:01Z","timestamp":1785894481600,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Project of Natural Science Foundation of Hebei Province","award":["H2023206055"],"award-info":[{"award-number":["H2023206055"]}]},{"name":"Scientific Research Foundation of Health Commission of Hebei Province","award":["20240391"],"award-info":[{"award-number":["20240391"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54291-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T01:54:41Z","timestamp":1779846881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of adiponectin and cytokines in Amyotrophic lateral sclerosis: assessment of disease progression and survival status"],"prefix":"10.1038","volume":"16","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"5","key":"54291_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","volume":"21","author":"SA Goutman","year":"2022","unstructured":"Goutman, S. A. et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 21(5), 465\u2013479 (2022).","journal-title":"Lancet Neurol."},{"issue":"10360","key":"54291_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman, E. L. et al. Amyotrophic lateral sclerosis. Lancet 400 (10360), 1363\u20131380 (2022).","journal-title":"Lancet"},{"issue":"1","key":"54291_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","volume":"17","author":"R Chia","year":"2018","unstructured":"Chia, R., Chi\u00f2, A. & Traynor, B. J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 17(1), 94\u2013102 (2018).","journal-title":"Lancet Neurol."},{"key":"54291_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/mus.10191","volume":"26","author":"PL McGeer","year":"2002","unstructured":"McGeer, P. L. & McGeer, E. G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459\u2013470 (2002).","journal-title":"Muscle Nerve"},{"issue":"10","key":"54291_CR5","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1172\/JCI90609","volume":"127","author":"T Chitnis","year":"2017","unstructured":"Chitnis, T. & Weiner, H. L. CNS inflammation and neurodegeneration. J. Clin. Invest. 127 (10), 3577\u20133587 (2017).","journal-title":"J. Clin. Invest."},{"issue":"4","key":"54291_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.immuni.2019.03.016","volume":"50","author":"TR Hammond","year":"2019","unstructured":"Hammond, T. R., Marsh, S. E. & Stevens, B. Immune signaling in neurodegeneration. Immunity 50(4), 955\u2013974 (2019).","journal-title":"Immunity"},{"issue":"11","key":"54291_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112759","volume":"20","author":"L Moreno-Martinez","year":"2019","unstructured":"Moreno-Martinez, L., Calvo, A. C., Mu\u00f1oz, M. J. & Osta, R. Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis?. Int. J. Mol. Sci. 20(11), 2759 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"54291_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1212\/01.wnl.0000333251.36681.a5","volume":"72","author":"RM Mitchell","year":"2009","unstructured":"Mitchell, R. M. et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 72 (1), 14\u201319 (2009).","journal-title":"Neurology"},{"key":"54291_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12974-015-0350-4","volume":"12","author":"J Ehrhart","year":"2015","unstructured":"Ehrhart, J. et al. Humoral factors in ALS patients during disease progression. J. Neuroinflammation. 12, 127 (2015).","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"54291_CR10","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1212\/NXI.0000000000000244","volume":"3","author":"CH Lu","year":"2016","unstructured":"Lu, C. H. et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3(4), e244 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"54291_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1468-1331.2009.02560.x","volume":"16","author":"J Kuhle","year":"2009","unstructured":"Kuhle, J. et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 16(6), 771\u20134 (2009).","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"54291_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/biomedicines10020354","volume":"10","author":"MA Leone","year":"2022","unstructured":"Leone, M. A. et al. Neutrophils-to-lymphocyte ratio is associated with progression and overall survival in amyotrophic lateral sclerosis. Biomedicines 10(2), 354 (2022).","journal-title":"Biomedicines"},{"issue":"1","key":"54291_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40478-025-02130-9","volume":"13","author":"C Benito-Casado","year":"2025","unstructured":"Benito-Casado, C. et al. White adipose tissue undergoes pathological dysfunction in the TDP-43A315T mouse model of amyotrophic lateral sclerosis (ALS). Acta Neuropathol. Commun. 13 (1), 213 (2025).","journal-title":"Acta Neuropathol. Commun."},{"issue":"23","key":"54291_CR14","doi-asserted-by":"publisher","first-page":"14982","DOI":"10.3390\/ijms232314982","volume":"23","author":"TV Kirichenko","year":"2022","unstructured":"Kirichenko, T. V. et al. The Role of Adipokines in Inflammatory Mechanisms of Obesity. Int. J. Mol. Sci. 23 (23), 14982 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"54291_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12974-017-0861-2","volume":"14","author":"P Bossolasco","year":"2017","unstructured":"Bossolasco, P. et al. Adiponectin levels in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients: Possible influence on neuroinflammation?. J. Neuroinflammation. 14(1), 85 (2017).","journal-title":"J. Neuroinflammation."},{"issue":"1\u20132","key":"54291_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cell.2014.12.019","volume":"160","author":"L Liu","year":"2015","unstructured":"Liu, L. et al. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160 (1\u20132), 177\u2013190 (2015).","journal-title":"Cell"},{"issue":"1","key":"54291_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12974-016-0530-x","volume":"13","author":"A Parimisetty","year":"2016","unstructured":"Parimisetty, A. et al. Secret talk between adipose tissue and central nervous system via secreted factors-An emerging frontier in the neurodegenerative research. J. Neuroinflammation 13(1), 67 (2016).","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"54291_CR18","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1002\/jcsm.13618","volume":"15","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. Prognostic value of systemic inflammation, nutritional status and sarcopenia in patients with amyotrophic lateral sclerosis. J. Cachexia Sarcopenia Muscle 15(6), 2743\u20132755 (2024).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"6","key":"54291_CR19","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/jnnp-2015-310998","volume":"87","author":"J Labra","year":"2016","unstructured":"Labra, J., Menon, P., Byth, K., Morrison, S. & Vucic, S. Rate of disease progression: A prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry 87(6), 628\u201332 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"54291_CR20","doi-asserted-by":"publisher","first-page":"1802237","DOI":"10.1183\/13993003.02237-2018","volume":"53","author":"J Ackrivo","year":"2019","unstructured":"Ackrivo, J. et al. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur. Respir. J. 53(4), 1802237 (2019).","journal-title":"Eur. Respir. J."},{"issue":"1\u20132","key":"54291_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum, J. M. et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. 169 (1\u20132), 13\u201321 (1999).","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"54291_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13054-025-05516-2","volume":"29","author":"S Gianoli","year":"2025","unstructured":"Gianoli, S., Tang, J., Odegard, K. C., Yuki, K. & Koutsogiannaki, S. Harnessing adiponectin for sepsis: Current knowledge, clinical insights and future therapies. Crit. Care 29(1), 300 (2025).","journal-title":"Crit. Care"},{"issue":"1","key":"54291_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13024-016-0136-x","volume":"11","author":"RC Ng","year":"2016","unstructured":"Ng, R. C. et al. Chronic adiponectin deficiency leads to Alzheimer\u2019s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice. Mol. Neurodegener. 11 (1), 71 (2016).","journal-title":"Mol. Neurodegener"},{"issue":"7","key":"54291_CR24","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki, T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116(7), 1784\u20131792 (2006).","journal-title":"J. Clin. Invest."},{"issue":"7","key":"54291_CR25","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2337\/dc09-1392","volume":"33","author":"A Mente","year":"2010","unstructured":"Mente, A. et al. Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care. 33 (7), 1629\u20131634 (2010).","journal-title":"Diabetes Care"},{"key":"54291_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1337442","volume":"15","author":"J Shen","year":"2024","unstructured":"Shen, J., Wang, X., Wang, M. & Zhang, H. Potential molecular mechanism of exercise reversing insulin resistance and improving neurodegenerative diseases. Front. Physiol. 15, 1337442 (2024).","journal-title":"Front. Physiol."},{"issue":"9","key":"54291_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/CIRCRESAHA.109.198044","volume":"104","author":"G Krenning","year":"2009","unstructured":"Krenning, G., Moonen, J. R. & Harmsen, M. C. Pleiotropism of adiponectin: Inflammation, neovascularization, and fibrosis. Circ. Res. 104(9), 1029\u20131031 (2009).","journal-title":"Circ. Res."},{"issue":"1","key":"54291_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12974-024-03066-y","volume":"21","author":"RC Ng","year":"2024","unstructured":"Ng, R. C. et al. Liver-specific adiponectin gene therapy suppresses microglial NLRP3-inflammasome activation for treating Alzheimer\u2019s disease. J. Neuroinflammation. 21 (1), 77 (2024).","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"54291_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI59660","volume":"122","author":"JP Thaler","year":"2012","unstructured":"Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122 (1), 153\u2013162 (2012).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"54291_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13578-021-00587-4","volume":"11","author":"B Roy","year":"2021","unstructured":"Roy, B. & Palaniyandi, S. S. Tissue-specific role and associated downstream signaling pathways of adiponectin. Cell. Biosci. 11 (1), 77 (2021).","journal-title":"Cell. Biosci."},{"issue":"1","key":"54291_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s13311-021-01159-7","volume":"19","author":"C Tallon","year":"2022","unstructured":"Tallon, C. et al. Dendrimer-2PMPA delays muscle function loss and denervation in a murine model of amyotrophic lateral sclerosis. Neurotherapeutics 19(1), 274\u2013288 (2022).","journal-title":"Neurotherapeutics"},{"issue":"11","key":"54291_CR32","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1093\/brain\/awad202","volume":"146","author":"JM Shefner","year":"2023","unstructured":"Shefner, J. M. et al. Skeletal muscle in amyotrophic lateral sclerosis. Brain 146 (11), 4425\u20134436 (2023).","journal-title":"Brain"},{"issue":"5","key":"54291_CR33","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1212\/NXI.0000000000000138","volume":"2","author":"T Furukawa","year":"2015","unstructured":"Furukawa, T. et al. CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. Neurol. Neuroimmunol. Neuroinflamm. 2(5), e138 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"54291_CR34","doi-asserted-by":"publisher","first-page":"20862","DOI":"10.1038\/s41598-020-77564-3","volume":"10","author":"MR Strickland","year":"2020","unstructured":"Strickland, M. R. et al. IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis. Sci. Rep. 10 (1), 20862 (2020).","journal-title":"Sci. Rep."},{"issue":"3","key":"54291_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1523\/JNEUROSCI.0854-15.2016","volume":"36","author":"M Gravel","year":"2016","unstructured":"Gravel, M. et al. IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded Superoxide Dismutase 1. J. Neurosci. 36(3), 1031\u20131048 (2016).","journal-title":"J. Neurosci."},{"issue":"7","key":"54291_CR36","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/cells12071016","volume":"12","author":"P Fabbrizio","year":"2023","unstructured":"Fabbrizio, P. et al. Intramuscular IL-10 administration enhances the activity of myogenic precursor cells and improves motor function in ALS mouse model. Cells 12(7), 1016 (2023).","journal-title":"Cells"},{"issue":"2","key":"54291_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020423","volume":"19","author":"S Garbuzova-Davis","year":"2018","unstructured":"Garbuzova-Davis, S., Ehrhart, J., Sanberg, P. R. & Borlongan, C. V. Potential role of humoral IL-6 cytokine in mediating pro-inflammatory endothelial cell response in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 19(2), 423 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"54291_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.bbi.2025.06.021","volume":"129","author":"G Risby-Jones","year":"2025","unstructured":"Risby-Jones, G. et al. IL-6 trans-signalling is elevated in ALS models and drives TDP-43 induced inflammatory responses in microglia. Brain. Behav. Immun. 129, 296\u2013304 (2025).","journal-title":"Brain. Behav. Immun."},{"issue":"6","key":"54291_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000631","volume":"6","author":"M Wosiski-Kuhn","year":"2019","unstructured":"Wosiski-Kuhn, M., Robinson, M. & Strupe, J. IL6 receptorAla variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 6(6), e631 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"54291_CR40","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 90(8), 870\u2013881 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"6","key":"54291_CR41","doi-asserted-by":"publisher","first-page":"e70241","DOI":"10.1111\/ene.70241","volume":"32","author":"A Bombaci","year":"2025","unstructured":"Bombaci, A. et al. Peripherin: A Novel Early Diagnostic and Prognostic Plasmatic Biomarker in Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 32 (6), e70241 (2025).","journal-title":"Eur. J. Neurol."},{"key":"54291_CR42","doi-asserted-by":"publisher","first-page":"105323","DOI":"10.1016\/j.ebiom.2024.105323","volume":"108","author":"M Benatar","year":"2024","unstructured":"Benatar, M. et al. Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: Validation and implications for clinical trial design and analysis. EBioMedicine 108, 105323 (2024).","journal-title":"EBioMedicine"},{"issue":"6","key":"54291_CR43","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/jcm12062367","volume":"12","author":"A Bombaci","year":"2023","unstructured":"Bombaci, A. et al. Plasma CHI3L1 in Amyotrophic Lateral Sclerosis: A Potential Differential Diagnostic Biomarker. J. Clin. Med. 12 (6), 2367 (2023).","journal-title":"J. Clin. Med."},{"issue":"6","key":"54291_CR44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/jnnp-2021-327877","volume":"93","author":"P Masrori","year":"2022","unstructured":"Masrori, P. et al. Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 93 (6), 681\u2013682 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl 1","key":"54291_CR45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0022-510X(97)00237-2","volume":"152","author":"JM Cedarbaum","year":"1997","unstructured":"Cedarbaum, J. M. & Stambler, N. Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials. J. Neurol. Sci. 152(Suppl 1), S1-9 (1997).","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"54291_CR46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni, S. et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl. J. Med. 383 (10), 919\u2013930 (2020).","journal-title":"N Engl. J. Med."},{"issue":"14","key":"54291_CR47","doi-asserted-by":"crossref","first-page":"e1610","DOI":"10.1212\/WNL.0000000000007242","volume":"92","author":"LH van den Berg","year":"2019","unstructured":"van den Berg, L. H. et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 92 (14), e1610\u2013e1623 (2019).","journal-title":"Neurology"},{"key":"54291_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1552949","volume":"19","author":"Y Hong","year":"2025","unstructured":"Hong, Y. et al. The systemic inflammation markers as potential predictors of disease progression and survival time in amyotrophic lateral sclerosis. Front. Neurosci. 19, 1552949 (2025).","journal-title":"Front. Neurosci."},{"issue":"1","key":"54291_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57366-y","volume":"10","author":"SJ Choi","year":"2020","unstructured":"Choi, S. J. et al. High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis. Sci. Rep. 10(1), 428 (2020).","journal-title":"Sci. Rep."},{"issue":"2","key":"54291_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura, F. et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66 (2), 265\u2013267 (2006).","journal-title":"Neurology"},{"issue":"8","key":"54291_CR51","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/archneur.63.8.1139","volume":"63","author":"A Czaplinski","year":"2006","unstructured":"Czaplinski, A., Yen, A. A., Simpson, E. P. & Appel, S. H. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: Is the natural history of amyotrophic lateral sclerosis changing?. Arch. Neurol. 63(8), 1139\u20131143 (2006).","journal-title":"Arch. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54291-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:02:46Z","timestamp":1785891766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54291-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54291"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54291-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8710375\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Second Hospital of Hebei Medical University (Approval No. 2024-R285). Written informed consent was obtained from all patients or their legal representatives prior to participation in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24116"}}